Xenitra (ASX: XEN) has reported preliminary unaudited third-quarter sales of $8.3 million, up more than 300% on the second quarter, as the company builds momentum across its nutritionals business and broadens its higher-margin product channels.
March sales alone exceeded $4m, bringing the business close to a full recovery of the annualised sales levels achieved in the 2024 financial year after a period of restructuring and turnaround.
The stronger quarter came alongside the acquisition of Hong Kong Fukang Trading, which gives Xenitra a fully operational platform for its over-the-counter (OTC) medicines division in Hong Kong and China.
The company has also locked in a firmer revenue base for the coming year through its recently announced $30m strategic partnership with Rockcheck Group for Danone products, which underpinned the quarter’s sales lift in nutritionals.
Sales Recovery Strengthens Core Business
Xenitra’s third-quarter growth was driven by its nutritionals business, which sits within a broader Asian sales ecosystem spanning business-to-business wholesale, retail distribution, and major ecommerce platforms.
The company has generated more than $70m in sales since 2024 across its fast-moving consumer goods, nutraceuticals and OTC medicine operations.
Chair Anthony Noble said the quarter’s performance had been delivered through a leaner and more focused structure after a year of business restructuring and renewal, providing a solid base from which to grow into multiple new markets aligned with Xenitra’s existing strategy and distribution strengths.
“The company has also launched two new and higher margin sales channels, OTC Medicines and the Blockchain Tokenised sales, [which] represent completely new sources of future revenue growth, with significantly higher gross margins,” Mr Noble said.
“The value of this work is not reflected in this strong performance in Q3, but will begin to deliver sales in Q4.”
Fukang Deal Opens OTC Channel
Xenitra acquired 100% of Fukang along with the assets needed to operate the OTC medicines business, including a Hong Kong pharmaceutical licence and associated premises lease, a JD.com store deposit, a Class 35 trademark registration, a warehouse logistics service deposit with Hong Kong Kanghong Pharmaceutical Group, and inventory on hand.
The total cost for the shares, deposits and acquired assets was ¥469,243, or approximately A$100,000.
The acquisition follows Xenitra’s authorisation on 18 December 2025 to operate under a Hong Kong pharmaceutical wholesale licence and launch its cross-border OTC medicines business.
Xenitra said Fukang’s established online shopfronts, customer databases and experienced local team will support a meaningful expansion of OTC medicine sales into the China market under the Hong Kong pharmaceutical licence.
New Channels Set Up Next Phase
Mr Noble said the acquisition of Fukang had put in place the required team and established online presence for the OTC medicines division, while the launch of the OPAL token had initiated Xenitra’s blockchain tokenised Web3 sales ecosystem anchored in real-world assets.
“Having this Hong Kong pharmaceutical licence in place will allow the company to bring more new products into the China market seamlessly, leveraging established shopfronts, customer databases, and a highly experienced team on the ground,” he added.
Rockcheck has approved Xenitra as a broader supplier to the conglomerate, creating scope for additional product sales that could add further revenue.
With sales recovering strongly, a larger Danone-linked nutritionals base in place and the Fukang acquisition now folded into operations, Xenitra enters the fourth quarter with both a rebuilt core revenue platform and two new channels positioned to begin contributing sales.
